Gemcitabine-induced Cell Death in Lung Cancer Cells: the Role of p53.
10.4046/trd.2002.53.3.275
- Author:
Doh Hyung KIM
1
;
Wha Shim YONG
;
Eun Kyung CHOI
;
Youn Seup KIM
;
Jae Seuk PARK
;
Young Koo JEE
;
Kye Young LEE
Author Information
1. Department of Internal Medicine, Dankook University College of Medicine, Chonan, Korea. kyleemd@anseo.dankook.ac.kr
- Publication Type:Original Article
- Keywords:
Gemcitabine;
Cell death;
p53;
Lung cancer
- MeSH:
Humans;
Lung Neoplasms;
Genes, p53;
Antimetabolites
- From:Tuberculosis and Respiratory Diseases
2002;53(3):275-284
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Gemcitabine is a new anti-cancer agent for treating non-small cell lung cancer. Functioning as an antimetabolite, it induces anti-cancer effects by suppressing DNA synthesis after being incorporated into the DNA as a cytosine arabinoside analogue. When Gemcitabine is incorporated into the DNA, the p53 gene may be activated by induction of the DNA defect. However, there are a few studies on the molecular mechanisms of Gemcitabine-induced cell death. This study examined the role of p53 in Gemcitabine-induced cell death. METHODS: A549 and NCl-H358 lung cancer cells were used in this study. The cell viability test was done using a MTT assay at Gemcitabine concentrations of 10nM, 100nM, 1uM, 10uM and 100uM. A FACScan analysis with propium iodide staining was used for the cell cycle analysis. Western blot analysis was done to investigate the extent of p53 activation. For the functional knock-out of p53, stable A549-E6 cells and H358-E6 cells were transfected pLXSN-16E6SD which is over expresses the human papilloma virus E6 protein that constantly degrades p53 protein. The functional knock out of p53 was confirmed by Western blot analysis after treatment with a DNA damaging agent, doxorubicine. RESULTS: Gemcitabine exhibited cell toxicity in dose-dependent fashion. The cell cycle analysis resulted in an S phase arrest. Western blot analysis significant p53 activation in time-dependent manner. Gemcitabine-induced cytotoxicity was reduced by 20-30% in the A549-E6 cells and the 30-40% in H358-E6 cells when compared with the A549-neo and H358-neo control cells. CONCLUSION: Gemcitabine induces an S phase arrest, as expected for the anti-metabolite, and activates the p53 gene. Furthermore, p53 might play an important role in Gemcitabine-induced cell death. Further investigation into the molecular mechanisms on how Gemcitabine activates the p53 gene and its signaling pathway are recommended.
